Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study
Recommended Citation
Riva N, Bertoletti L, Chistolini A, De Stefano V, Barbar S, Donadini MP, Sartori MT, Couturaud F, Sartori M, Gatt A, Cohen O, Fantoni C, Kaatz S, Mavri A, Mahé I, Catella J, Ruiz-Artacho P, Ghigliotti G, Jara-Palomares L, Podda GM, Squizzato A, Rojnuckarin P, Leentjens J, Sevestre MA, Ageno W. Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study. Res Pract Thromb Haemost. 2026;10(3):103462.
Document Type
Article
Publication Date
3-1-2026
Publication Title
Res Pract Thromb Haemost
Keywords
Humans, Cross-Sectional Studies, Female, Venous Thromboembolism, Administration, Oral, Male, Middle Aged, Practice Patterns, Physicians', Aged, Prospective Studies, Anticoagulants, Adult, Rivaroxaban, Factor Xa Inhibitors, Venous Thrombosis, Pyrazoles, Pyridones, Registries
Abstract
BACKGROUND: Unusual site venous thromboembolism (USVTE) presents therapeutic challenges. Direct oral anticoagulants (DOACs) are increasingly prescribed despite limited evidence from clinical trials.
OBJECTIVES: This cross-sectional analysis aimed to describe DOAC prescription patterns and rationale for choosing DOACs for USVTE treatment in real-life clinical practice.
METHODS: The Direct oral anticoagulants in Unusual Site venous Thromboembolism study (NCT03778502) is an international, multicenter, prospective, observational registry. Adult patients with objectively diagnosed USVTE (years 2018-2023) treated with DOACs were included. Information was collected on patient characteristics, USVTE location, anticoagulant treatment, and rationale for starting DOACs.
RESULTS: In total, 349 patients were included from 23 centers in 9 countries. The most common USVTE were splanchnic vein thrombosis (
CONCLUSION: DOACs are increasingly prescribed for USVTE owing to their ease of use and perceived safety, but mainly after initial treatment with parenteral anticoagulation. Further evidence is still needed to support their use in the acute phase.
Medical Subject Headings
Humans; Cross-Sectional Studies; Female; Venous Thromboembolism; Administration, Oral; Male; Middle Aged; Practice Patterns, Physicians'; Aged; Prospective Studies; Anticoagulants; Adult; Rivaroxaban; Factor Xa Inhibitors; Venous Thrombosis; Pyrazoles; Pyridones; Registries
PubMed ID
42079675
Volume
10
Issue
3
First Page
103462
Last Page
103462
